Brief: Caplin Point Laboratories Unit Gets USFDA Nod For Ropivacaine Hydrochloride Injection
13/04/2020 04:46
April 13 (Reuters) - Caplin Point Laboratories Ltd
CAPL.NS :
* UNIT GETS USFDA NOD FOR ROPIVACAINE HYDROCHLORIDE
INJECTION
* WORKING ON 35 INJECTABLE AND OPHTHALMIC PRODUCTS, TO BE
FILED
OVER NEXT 4 YEARS
Source text for Eikon: ID:
Further company coverage: CAPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees